{
  "nct_id": "NCT29492472",
  "indication": "Asthma",
  "phase": "Phase 1/2",
  "sample_size": 39,
  "duration_weeks": 22,
  "dropout_rate": 0.12,
  "blinding": "single-blind",
  "control_arm": "active comparator",
  "primary_endpoints": [
    "Asthma exacerbation reduction"
  ],
  "secondary_endpoints": [
    "FEV1 improvement",
    "ACQ score improvement"
  ],
  "outcome_summary": "Demonstrated superior efficacy compared to placebo",
  "success": 1,
  "start_date": "2020-04-17",
  "completion_date": "2020-09-18"
}